Antibody therapy represents one of the most promising and actively pursued therapeutic approaches for neurodegenerative diseases. This class of biologics leverages the specificity of the immune system to target pathological proteins, modulate cellular pathways, and potentially halt or slow disease progression in conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders [PMID:34220465]. The development of monoclonal antibodies as therapeutics has revolutionized modern medicine, with the first therapeutic monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) in 1986 [PMID:2684164]. Since then, over 100 monoclonal antibodies have received regulatory approval for various indications, and their application has expanded beyond oncology and autoimmune diseases into the field of neuroscience [PMID:35867012].
Neurodegenerative diseases share common pathophysiological features, including the accumulation of misfolded proteins, neuroinflammation, synaptic dysfunction, and progressive neuronal loss. Antibody-based therapies aim to address these mechanisms through several approaches: directly targeting and neutralizing pathogenic proteins, enhancing their clearance, or modulating the immune response to create a more favorable central nervous system (CNS) environment [PMID:35658842]. The therapeutic potential of antibodies stems from their high affinity and specificity for their targets, which theoretically allows for precise intervention in disease processes while minimizing off-target effects.
The development of antibody therapies for neurodegeneration has accelerated dramatically over the past two decades, driven by advances in antibody engineering, a deeper understanding of disease biology, and the urgent unmet medical need represented by these conditions. Despite significant challenges, including the difficulty of delivering therapeutic antibodies across the blood-brain barrier (BBB), several antibody therapies have now received regulatory approval, marking a new era in the treatment of neurodegenerative diseases [PMID:37352023].
The concept of using antibodies as therapeutic agents dates back to the late 19th century when Emil von Behring discovered that antibodies could neutralize toxins [PMID:11844851]. However, the modern era of monoclonal antibody therapy began in 1975 when Georges Köhler and César Milstein developed hybridoma technology, enabling the production of antibodies with defined specificity [PMID:4630588]. This breakthrough earned them the Nobel Prize in Physiology or Medicine in 1984 and paved the way for the development of therapeutic monoclonal antibodies.
The first therapeutic monoclonal antibodies were murine-based, but their clinical use was limited by human anti-mouse antibody (HAMA) responses that reduced efficacy and caused serum sickness-like reactions [PMID:1645306]. The development of chimeric antibodies, in which the variable regions of murine antibodies are fused to human constant regions, reduced immunogenicity while maintaining target specificity [PMID:2676281]. Further advances led to humanized antibodies, which contain only complementarity-determining regions (CDRs) from murine sources, and fully human antibodies generated through phage display or transgenic mouse technologies [PMID:2190392].
Therapeutic antibodies have evolved considerably beyond the standard immunoglobulin G (IgG) format. Various antibody engineering strategies have been employed to enhance efficacy, improve pharmacokinetics, or reduce costs [PMID:33741711]. Key antibody formats include:
Fragment antigens binding (Fab) fragments consist of the variable regions of the heavy and light chains connected by a disulfide bond. These smaller fragments (approximately 50 kDa) have faster clearance from circulation but may have reduced efficacy due to shorter half-life and lack of Fc-mediated effector functions.
Single-chain variable fragments (scFv) contain only the variable regions linked by a flexible peptide. At approximately 25 kDa, these are even smaller than Fab fragments but may have reduced binding affinity due to the absence of the full antigen-binding site.
Bispecific antibodies are engineered to recognize two different antigens simultaneously, enabling novel therapeutic mechanisms such as redirecting T cells to tumor cells or simultaneously targeting two pathogenic proteins [PMID:31737537].
Fc-engineered antibodies have modified Fc regions that alter binding to Fc receptors, potentially enhancing efficacy, reducing side effects, or extending half-life through engineered glycoengineering [PMID:31781666].
The identification of specific protein aggregates as central to neurodegeneration has enabled the rational design of antibody therapies. The major targets include amyloid-beta, tau, alpha-synuclein, and emerging targets such as TREM2.
Amyloid-beta (Aβ) peptides are derived from the amyloid precursor protein (APP) through sequential proteolytic cleavage by β- and γ-secretases. The aggregation of Aβ into soluble oligomers and insoluble plaques has long been considered a initiating event in Alzheimer's disease pathogenesis [PMID:12563030]. This "amyloid hypothesis" has driven extensive drug development efforts targeting Aβ, including antibody-based approaches.
Aβ-directed antibodies aim to reduce cerebral amyloid burden through several mechanisms: binding to soluble Aβ and preventing aggregation, promoting clearance of existing plaques via Fc-mediated microglial phagocytosis, or neutralizing toxic oligomeric species [PMID:25921056]. Several Aβ antibodies have advanced to late-stage clinical trials, with mixed results.
Aducanumab (Aduhelm) is a human IgG1 antibody that selectively targets aggregated Aβ, including both soluble oligomers and insoluble plaques. The EMERGE and ENGAGE Phase 3 trials initially failed to meet their primary endpoints in 2019, but subsequent analysis of expanded datasets revealed reduced clinical decline in patients receiving high-dose aducanumab, accompanied by significant reduction in amyloid plaque burden [PMID:33148843]. Based on these results, aducanumab received accelerated approval from the FDA in 2021, making it the first disease-modifying therapy for Alzheimer's disease [PMID:34552062]. However, the approval remained controversial due to conflicting trial results, and the European Medicines Agency (EMA) rejected its authorization.
Lecanemab (Leqembi) is a humanized IgG1 antibody that binds with high affinity to Aβ protofibrils, considered the most toxic form of Aβ. The CLARITY-AD Phase 3 trial demonstrated that lecanemab significantly reduced clinical decline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) compared to placebo at 18 months, with a 27% reduction in cognitive decline [PMID:36449457]. Lecanemab received full FDA approval in 2023, representing the first confirmation of clinical benefit in an anti-amyloid antibody. However, ARIA (amyloid-related imaging abnormalities) representing brain edema and hemorrhage occurred in approximately 21% of participants, requiring careful monitoring.
Donanemab is a humanized IgG1 antibody targeting a specific form of modified Aβ (pyroglutamate Aβ). The TRAILBLAZE-ALZ Phase 3 trial demonstrated that donanemab significantly slowed clinical progression, with 35% slower decline on iADRS (integrated Alzheimer's Disease Rating Scale) compared to placebo [PMID:37352023]. Based on these results, donanemab received FDA approval in 2024. Like other anti-amyloid antibodies, ARIA was observed in approximately 37% of treated patients.
Gantenerumab is a fully human IgG1 antibody that binds to both monomeric and aggregated Aβ. Despite showing amyloid reduction in the open-label GRADIENT extension study, the SCarlet RoAD and Marguerite RoAD Phase 3 trials failed to meet their primary endpoints, and development was discontinued [PMID:26235533].
Solanezumab is a humanized IgG1 antibody that binds to the mid-domain of Aβ, primarily targeting soluble monomeric Aβ. The EXPEDITION Phase 3 trials in mild-to-moderate AD failed to demonstrate cognitive benefit, and development was discontinued [PMID:25041470].
Tau proteins are microtubule-associated proteins that stabilize neuronal axons. In Alzheimer's disease and other tauopathies, tau becomes hyperphosphorylated, misfolds, and aggregates into neurofibrillary tangles (NFTs) that correlate closely with cognitive decline [PMID:12563028]. Tau pathology spreads prion-like through neural circuits, and targeting tau with antibodies has emerged as a complementary strategy to anti-amyloid therapies [PMID:28653647].
Anti-tau antibodies aim to prevent tau aggregation, promote clearance of existing tangles, or block the intercellular spread of pathological tau. Several antibodies have advanced to clinical development, with mixed results.
LMTM (Lademirsen) is an antisense oligonucleotide rather than an antibody, but anti-tau antibodies have included several candidates. Gantenerumab, mentioned above for its anti-amyloid activity, also binds to tau aggregates and has been studied in primary tauopathies. The TAURIEL trial evaluated gantenerumab in patients with mild cognitive impairment due to Alzheimer's disease, but primary endpoints were not met [PMID:33067454].
ABBV-8E12 (Cinomerersen) is a humanized IgG4 antibody targeting extracellular tau. A Phase 2 trial in progressive supranuclear palsy (PSP) showed acceptable safety but did not meet its primary endpoint of slowing clinical decline [PMID:33408464].
JNJ-63733657 is a fully human anti-tau IgG4 antibody that binds to phosphorylated tau. A Phase 1 study demonstrated target engagement and acceptable safety, supporting further development [PMID:35085352].
Semorinemab is a humanized IgG4 antibody that binds to the N-terminal region of tau. The Lauriet trial in moderate AD failed to meet its primary endpoint of reducing cognitive decline, though some secondary endpoints showed potential benefit [PMID:36653511].
Alpha-synuclein is a presynaptic protein that aggregates into Lewy bodies in Parkinson's disease and related disorders. The prion-like spread of alpha-synuclein pathology throughout the brain is thought to underlie disease progression [PMID:18986257]. Antibodies targeting alpha-synuclein aim to neutralize extracellular alpha-synuclein aggregates, prevent neuronal uptake, and potentially slow disease progression.
Prasinezumab (PRX002) is a humanized IgG1 antibody that binds to the C-terminus of alpha-synuclein. The PASADENA Phase 2 trial in early Parkinson's disease met its primary endpoint of safety and tolerability, and although clinical outcomes did not reach statistical significance at the primary analysis, longer-term follow-up suggested potential disease-modifying effects [PMID:34927027].
Cinomerersen (BIIB054) is a fully human IgG1 antibody that binds to alpha-synuclein and inhibits its aggregation. The SPARK Phase 2 trial in Parkinson's disease did not meet its primary endpoint of reducing clinical decline, though biomarker analyses suggested target engagement [PMID:35484277].
APO-810 (WVE-004) is an antibody designed to target pathological alpha-synuclein aggregates. Phase 1 studies are ongoing in multiple system atrophy (MSA), a rapidly progressive synucleinopathy [PMID:36708353].
Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell surface receptor expressed on microglia that plays a critical role in neuroinflammation and amyloid clearance. Rare coding variants in TREM2 increase the risk of Alzheimer's disease approximately three-fold, highlighting its importance in disease pathogenesis [PMID:23999529]. Microglial dysfunction contributes to neurodegeneration, and targeting TREM2 represents a novel therapeutic strategy.
AL002 (ALX0681) is a humanized IgG1 antibody that activates TREM2 signaling. Phase 1 studies demonstrated acceptable safety and evidence of target engagement in the central nervous system, supporting advancement to Phase 2 trials in early Alzheimer's disease [PMID:36734265].
SHT-305 is another TREM2-targeting antibody that entered clinical development but has shown limited public disclosure of results.
Other microglial targets under investigation include CD33, where genetic variants influence AD risk, and CSF1R, which modulates microglial survival and function [PMID:32877961].
Beyond the major protein aggregates, antibody therapies are being developed against several other targets:
Apolipoprotein E (ApoE) polymorphisms, particularly the ε4 allele, represent the strongest genetic risk factor for late-onset AD. antibodies targeting ApoE4 are being developed to reduce its pathogenic effects on amyloid deposition and neuroinflammation [PMID:29488665].
Alpha-1 antichymotrypsin (ACT) is an acute-phase protein that co-deposits with Aβ plaques and may accelerate aggregation. Antibodies targeting ACT are in preclinical development.
N-terminal pyroglutamate Aβ is a particularly neurotoxic modified form of Aβ that is found in early plaque deposits. Several antibodies targeting this modification have entered clinical trials.
Antibody therapies for neurodegeneration employ multiple mechanisms to exert their therapeutic effects. Understanding these mechanisms is crucial for optimizing drug design and predicting clinical outcomes.
The most straightforward mechanism involves antibodies binding to their target protein, thereby neutralizing its pathological activity. For extracellular proteins like soluble Aβ oligomers, this binding can prevent interactions with neuronal receptors, block aggregation, or simply sequester the protein in a form that cannot penetrate cells [PMID:25282378].
For intracellular targets, antibodies must either enter cells or act on extracellular domains of membrane-bound proteins. Intracellular delivery of antibodies remains challenging, though innovative approaches such as engineered toxin fragments or viral vectors are being explored.
When antibodies bind to their targets, the Fc region can engage Fc receptors (FcγRs) on immune cells, particularly microglia in the central nervous system. This engagement can trigger several protective mechanisms:
Phagocytosis (antibody-dependent cellular phagocytosis, ADCP): Fc-engaged microglia can engulf and destroy antibody-coated targets, including amyloid plaques. This mechanism likely contributes significantly to the amyloid-reducing effects observed with aducanumab, lecanemab, and donanemab [PMID:31745706].
Complement activation can lead to target cell lysis through the membrane attack complex (MAC). However, complement activation in the brain may contribute to inflammatory side effects, and antibody engineering to modulate Fc effector function is an active area of research.
Antibody-dependent cellular cytotoxicity (ADCC) involves natural killer (NK) cells and other cytotoxic cells recognizing Fc-bound targets. The relative importance of ADCC in the central nervous system compared to peripheral tissues is unclear.
Beyond directly clearing pathological proteins, antibodies can modulate the immune environment in ways that may be beneficial in neurodegeneration. For example, anti-Aβ antibodies may reduce neuroinflammation by decreasing the load of pro-inflammatory aggregates, or TREM2-activating antibodies may shift microglia toward a protective phenotype [PMID:35550260].